Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis, December 2012
The global pharmaceutical industry is expected to reach $1,241 billion by 2016, growing at a CAGR of 5.7%. The fragmented market has observed some changes in the competitive landscape during the last five years. The top players are expanding their footprints in the emerging markets of China, India, Brazil, Latin America, and Eastern Europe. They are strengthening their technological and R&D structure by targeted merger and acquisition activities to help develop and market innovative drugs.
Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis on the global drugs industry and presents its findings in “Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis.” This report briefly discusses the subject companies, their geographic footprints, financial metrics, market performance, marketing and corporate strategies, and provides SWOT analysis of each.
The report indicates that increased regulation of the pharmaceutical industry is expected to increase the industry’s cost structure and reduce revenue as getting drugs to market becomes a longer and more expensive process. Regulatory approval for the introduction of biogenerics/biosimilars, generic versions of biologic drugs, increases the threat of uncertainty to the pharmaceutical market.
Lucintel projects the major drivers of the industry. Growth in sectors such as health awareness among populations, R&D expenditures, sales of prescribed medicine and demand for generic medicines are expect to continue to provide huge demand for medicines. Various governments’ increased spending in infectious and chronic degenerative diseases as well as anti-diabetes and cardiovascular drugs have driven the growth in sales of the pharmaceutical industry.
The report gives an overview of the top five global pharmaceutical companies:
This report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global pharmaceutical companies industry. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business
Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis on the global drugs industry and presents its findings in “Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis.” This report briefly discusses the subject companies, their geographic footprints, financial metrics, market performance, marketing and corporate strategies, and provides SWOT analysis of each.
The report indicates that increased regulation of the pharmaceutical industry is expected to increase the industry’s cost structure and reduce revenue as getting drugs to market becomes a longer and more expensive process. Regulatory approval for the introduction of biogenerics/biosimilars, generic versions of biologic drugs, increases the threat of uncertainty to the pharmaceutical market.
Lucintel projects the major drivers of the industry. Growth in sectors such as health awareness among populations, R&D expenditures, sales of prescribed medicine and demand for generic medicines are expect to continue to provide huge demand for medicines. Various governments’ increased spending in infectious and chronic degenerative diseases as well as anti-diabetes and cardiovascular drugs have driven the growth in sales of the pharmaceutical industry.
The report gives an overview of the top five global pharmaceutical companies:
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sanofi-Aventis
This report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global pharmaceutical companies industry. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business
1. EXECUTIVE SUMMARY
2. MARKET DEFINITION AND SCOPE
3. MARKET OPPORTUNITY
4. COMPETITIVE BENCHMARKING (FINANCIAL AND MARKET)
Company Profile on Following Parameters
Company Overview
Benchmarking (Financial & Market)
SWOT Analysis
Product Positioning
Marketing Strategy and Tactics
Corporate Strategy
5. COMPANY PROFILE ON GLAXOSMITHKLINE PLC
6. COMPANY PROFILE ON MERCK & CO., INC.
7. COMPANY PROFILE ON NOVARTIS AG
8. COMPANY PROFILE ON PFIZER, INC.
9. COMPANY PROFILE ON SANOFI-AVENTIS
2. MARKET DEFINITION AND SCOPE
3. MARKET OPPORTUNITY
4. COMPETITIVE BENCHMARKING (FINANCIAL AND MARKET)
Company Profile on Following Parameters
Company Overview
Benchmarking (Financial & Market)
SWOT Analysis
Product Positioning
Marketing Strategy and Tactics
Corporate Strategy
5. COMPANY PROFILE ON GLAXOSMITHKLINE PLC
6. COMPANY PROFILE ON MERCK & CO., INC.
7. COMPANY PROFILE ON NOVARTIS AG
8. COMPANY PROFILE ON PFIZER, INC.
9. COMPANY PROFILE ON SANOFI-AVENTIS
LIST OF FIGURES AND CHARTS
CHAPTER 3. Market Opportunity
Figure 3.1: Supply chain for pharmaceutical market
Figure 3.2: Global pharmaceutical industry annual trend 2006-2011 (US $B)
Figure 3.3: Global pharmaceutical industry regional trend 2006-2011 (US $B)
Figure 3.4: Global pharmaceutical industry regional trend 2006-2011 (%)
Figure 3.5: Global pharmaceutical industry segment trend 2006-2011 (US $B)
Figure 3.6: Global pharmaceutical industry segment trend 2006-2011 (%)
Figure 3.7: Global pharmaceutical industry opportunity by region
Figure 3.8: Global pharmaceutical industry opportunity by segment
CHAPTER 4.Competitive Benchmarking (Financial and Market)
Figure 4.1: Top five pharmaceutical companies – financial benchmarking
Figure 4.2: Global top five pharmaceutical companies gross profit and net profit analysis – 2011
Figure 4.3: Financial analysis – growth leadership quadrant (2011)
Figure 4.4: Market share of top players 2006
Figure 4.5: Market share of top players 2011
Figure 4.6: 2006 Market share analysis
Figure 4.7: 2011 Market share analysis
Figure 4.8: Global market share analysis 2011
Figure 4.9: Global market fragmentation 2011
Figure 4.10: Market value North America: (US $B)
Figure 4.11: Market value Europe: (US $B)
Figure 4.12: Market value Asia Pacific: (US $B)
Figure 4.13: Market value Row: (US $B)
Figure 4.14: Regional revenue evaluation 2011(US $M)
Figure 4.15: Regional revenue evaluation 2011(%)
Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)
Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)
Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)
Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)
Figure 4.20: Lucintel triad - top five major players
CHAPTER 5. Company Profile of GlaxoSmithKline Plc
Figure 5.1: GlaxoSmithKline Plc’s revenue by business structure 2011
Figure 5.2: Lucintel Triad – GlaxoSmithKline Plc
Figure 5.3: Financial benchmarking GlaxoSmithKline Plc against top three and top five industry players’ average
Figure 5.4: Financial benchmarking of GlaxoSmithKline Plc against Top Five best
Figure 5.5: Global industry revenue trend Vs GlaxoSmithKline Plc (2007-2011) in US $B
Figure 5.6: Global market share trend for GlaxoSmithKline Plc (2007-2011) in (%)
Figure 5.7: North American industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.8: European industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.9: APAC industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.10: ROW industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.11: North American market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.12: European market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.13: APAC market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.14: ROW market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.15: GlaxoSmithKline Plc trend in R&D expenses 2007-2011 in US $M
Figure 5.16: GlaxoSmithKline Plc trend in R&D expenses percentage of total revenue
Figure 5.17: Comparison of GlaxoSmithKline Plc SE R&D expenditure Vs top three & top five players average 2011
Figure 5.18: GlaxoSmithKline Plc productivity 2007-2011 (US $M)
Figure 5.19: GlaxoSmithKline Plc fixed asset value 2007-2011 (US $M)
Figure 5.20: Strategic execution
CHAPTER 6. Company Profile of Merck & Co., Inc.
Figure 6.1: Merck & Co., Inc. revenue by business structure 2011
Figure 6.2: Lucintel triad – Merck & Co., Inc.
Figure 6.3: Financial benchmarking of Merck & Co., Inc. against top three and top five industry players’ average
Figure 6.4: Financial benchmarking of Merck & Co., Inc. against Top five best
Figure 6.5: Global industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.6: Global market share trend for Merck & Co., Inc. (2007-2011) in (%)
Figure 6.7: North American industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.8: European industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.9: APAC industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.10: ROW industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.11: North American market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.12: European market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.13: APAC market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.14: ROW market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.15: Merck & Co., Inc. trend in R&D expenses 2007-2011 in US $M
Figure 6.16: Merck & Co., Inc. trend in R&D expenses Percentage of total revenue
Figure 6.17: Comparison of Merck & Co., Inc. R&D expenditure vs top three & top five players average 2011
Figure 6.18: Merck & Co., Inc. productivity: 2007-2011 in (US $M)
Figure 6.19: Merck & Co., Inc. fixed asset value: 2007-2011 in (US $M)
Figure 6.20: Strategic execution
CHAPTER 7. Company Profile of Novartis AG
Figure 7.1: Novartis AG revenue by business structure 2011
Figure 7.2: Lucintel triad - Novartis AG
Figure 7.3: Financial benchmarking of Novartis AG against top three and top five industry players’ average
Figure 7.4: Financial benchmarking of Novartis AG against Top five best
Figure 7.5: Global industry revenue trend Vs Novartis AG (2007-2011) in (US $B)
Figure 7.6: Global market share trend for Novartis AG (2007-2011) in (%)
Figure 7.7: North American industry revenue trend Vs. Novartis AG 2007-2011 in (US $B)
Figure 7.8: European industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.9: APAC industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.10: ROW industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.11: North American market share trend Vs Novartis AG 2007-2011 in (%)
Figure 7.12: European market share trend Vs Novartis AG 2007-2011 in (%)
Figure 7.13: APAC market share trend Vs DuPont 2007-2011 in (%)
Figure 7.14: ROW market share trend Vs DuPont 2007-2011 in (%)
Figure 7.15: Novartis AG trend in R&D expenses 2007-2011 in US $M
Figure 7.16: Novartis AG trend in R&D expenses Percentage of total revenue
Figure 7.17: Comparison of Novartis AG SE R&D expenditure Vs top three & top five players average 2011
Figure 7.18: Novartis AG productivity: 2007-2011 in (US $M)
Figure 7.19: Novartis AG fixed asset value: 2007-2011 in (US $M)
Figure 7.20: Strategic execution
CHAPTER 8. Company Profile of Pfizer, Inc.
Figure 8.1: Pfizer, Inc. revenue by business structure 2011
Figure 8.2: Lucintel triad – Pfizer, Inc.
Figure 8.3: Financial benchmarking of Pfizer, Inc. against top three and top five industry players’ average
Figure 8.4: Financial benchmarking of Pfizer, Inc. against Top five best
Figure 8.5: Global industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.6: Global market share trend for Pfizer, Inc. (2007-2011) in (%)
Figure 8.7: North American industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.8: European industry revenue trend Vs Pfizer, Inc. l (2007-2011) in (US $B)
Figure 8.9: APAC industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.10: ROW industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.11: North American market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.12: European market share trend Vs Pfizer, Inc. l (2007-2011) in (%)
Figure 8.13: APAC market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.14: ROW market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.15: Pfizer, Inc. trend in R&D expenses 2007-2011 in US $M
Figure 8.16: Pfizer, Inc. trend in R&D expenses Percentage of total revenue
Figure 8.17: Comparison of Pfizer, Inc. R&D expenditure vs top three & top five players average 2011
Figure 8.18: Pfizer, Inc. productivity: 2007-2011 in (US $M)
Figure 8.19: Pfizer, Inc. fixed asset value: 2007-2011 in (US $M)
Figure 8.20: Strategic execution
CHAPTER 9. Company Profile of Sanofi-Aventis
Figure 9.1: Sanofi-Aventis revenue by business structure 2011
Figure 9.2: Lucintel triad – Sanofi-Aventis
Figure 9.3: Financial benchmarking of Sanofi-Aventis against top three and top five industry players’ average
Figure 9.4: Financial benchmarking of Sanofi-Aventis against Top five best
Figure 9.5: Global industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.6: Global market share trend for Sanofi-Aventis (2007-2011) in (%)
Figure 9.7: North American industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.8: European industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.9: APAC industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.10: ROW industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.11: North American market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.12: European market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.13: APAC market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.14: ROW market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.15: Sanofi-Aventis trend in R&D expenses 2007-2011 in US $M
Figure 9.16: Sanofi-Aventis trend in R&D expenses Percentage of total revenue
Figure 9.17: Comparison of Sanofi-Aventis R&D expenditure vs top three & top five players average 2011
Figure 9.18: Sanofi-Aventis productivity: 2007-2011 in (US $M)
Figure 9.19: Sanofi-Aventis fixed asset value: 2007-2011 in (US $M)
Figure 9.20: Strategic execution
CHAPTER 3. Market Opportunity
Figure 3.1: Supply chain for pharmaceutical market
Figure 3.2: Global pharmaceutical industry annual trend 2006-2011 (US $B)
Figure 3.3: Global pharmaceutical industry regional trend 2006-2011 (US $B)
Figure 3.4: Global pharmaceutical industry regional trend 2006-2011 (%)
Figure 3.5: Global pharmaceutical industry segment trend 2006-2011 (US $B)
Figure 3.6: Global pharmaceutical industry segment trend 2006-2011 (%)
Figure 3.7: Global pharmaceutical industry opportunity by region
Figure 3.8: Global pharmaceutical industry opportunity by segment
CHAPTER 4.Competitive Benchmarking (Financial and Market)
Figure 4.1: Top five pharmaceutical companies – financial benchmarking
Figure 4.2: Global top five pharmaceutical companies gross profit and net profit analysis – 2011
Figure 4.3: Financial analysis – growth leadership quadrant (2011)
Figure 4.4: Market share of top players 2006
Figure 4.5: Market share of top players 2011
Figure 4.6: 2006 Market share analysis
Figure 4.7: 2011 Market share analysis
Figure 4.8: Global market share analysis 2011
Figure 4.9: Global market fragmentation 2011
Figure 4.10: Market value North America: (US $B)
Figure 4.11: Market value Europe: (US $B)
Figure 4.12: Market value Asia Pacific: (US $B)
Figure 4.13: Market value Row: (US $B)
Figure 4.14: Regional revenue evaluation 2011(US $M)
Figure 4.15: Regional revenue evaluation 2011(%)
Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)
Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)
Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)
Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)
Figure 4.20: Lucintel triad - top five major players
CHAPTER 5. Company Profile of GlaxoSmithKline Plc
Figure 5.1: GlaxoSmithKline Plc’s revenue by business structure 2011
Figure 5.2: Lucintel Triad – GlaxoSmithKline Plc
Figure 5.3: Financial benchmarking GlaxoSmithKline Plc against top three and top five industry players’ average
Figure 5.4: Financial benchmarking of GlaxoSmithKline Plc against Top Five best
Figure 5.5: Global industry revenue trend Vs GlaxoSmithKline Plc (2007-2011) in US $B
Figure 5.6: Global market share trend for GlaxoSmithKline Plc (2007-2011) in (%)
Figure 5.7: North American industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.8: European industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.9: APAC industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.10: ROW industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.11: North American market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.12: European market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.13: APAC market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.14: ROW market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.15: GlaxoSmithKline Plc trend in R&D expenses 2007-2011 in US $M
Figure 5.16: GlaxoSmithKline Plc trend in R&D expenses percentage of total revenue
Figure 5.17: Comparison of GlaxoSmithKline Plc SE R&D expenditure Vs top three & top five players average 2011
Figure 5.18: GlaxoSmithKline Plc productivity 2007-2011 (US $M)
Figure 5.19: GlaxoSmithKline Plc fixed asset value 2007-2011 (US $M)
Figure 5.20: Strategic execution
CHAPTER 6. Company Profile of Merck & Co., Inc.
Figure 6.1: Merck & Co., Inc. revenue by business structure 2011
Figure 6.2: Lucintel triad – Merck & Co., Inc.
Figure 6.3: Financial benchmarking of Merck & Co., Inc. against top three and top five industry players’ average
Figure 6.4: Financial benchmarking of Merck & Co., Inc. against Top five best
Figure 6.5: Global industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.6: Global market share trend for Merck & Co., Inc. (2007-2011) in (%)
Figure 6.7: North American industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.8: European industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.9: APAC industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.10: ROW industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.11: North American market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.12: European market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.13: APAC market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.14: ROW market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.15: Merck & Co., Inc. trend in R&D expenses 2007-2011 in US $M
Figure 6.16: Merck & Co., Inc. trend in R&D expenses Percentage of total revenue
Figure 6.17: Comparison of Merck & Co., Inc. R&D expenditure vs top three & top five players average 2011
Figure 6.18: Merck & Co., Inc. productivity: 2007-2011 in (US $M)
Figure 6.19: Merck & Co., Inc. fixed asset value: 2007-2011 in (US $M)
Figure 6.20: Strategic execution
CHAPTER 7. Company Profile of Novartis AG
Figure 7.1: Novartis AG revenue by business structure 2011
Figure 7.2: Lucintel triad - Novartis AG
Figure 7.3: Financial benchmarking of Novartis AG against top three and top five industry players’ average
Figure 7.4: Financial benchmarking of Novartis AG against Top five best
Figure 7.5: Global industry revenue trend Vs Novartis AG (2007-2011) in (US $B)
Figure 7.6: Global market share trend for Novartis AG (2007-2011) in (%)
Figure 7.7: North American industry revenue trend Vs. Novartis AG 2007-2011 in (US $B)
Figure 7.8: European industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.9: APAC industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.10: ROW industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.11: North American market share trend Vs Novartis AG 2007-2011 in (%)
Figure 7.12: European market share trend Vs Novartis AG 2007-2011 in (%)
Figure 7.13: APAC market share trend Vs DuPont 2007-2011 in (%)
Figure 7.14: ROW market share trend Vs DuPont 2007-2011 in (%)
Figure 7.15: Novartis AG trend in R&D expenses 2007-2011 in US $M
Figure 7.16: Novartis AG trend in R&D expenses Percentage of total revenue
Figure 7.17: Comparison of Novartis AG SE R&D expenditure Vs top three & top five players average 2011
Figure 7.18: Novartis AG productivity: 2007-2011 in (US $M)
Figure 7.19: Novartis AG fixed asset value: 2007-2011 in (US $M)
Figure 7.20: Strategic execution
CHAPTER 8. Company Profile of Pfizer, Inc.
Figure 8.1: Pfizer, Inc. revenue by business structure 2011
Figure 8.2: Lucintel triad – Pfizer, Inc.
Figure 8.3: Financial benchmarking of Pfizer, Inc. against top three and top five industry players’ average
Figure 8.4: Financial benchmarking of Pfizer, Inc. against Top five best
Figure 8.5: Global industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.6: Global market share trend for Pfizer, Inc. (2007-2011) in (%)
Figure 8.7: North American industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.8: European industry revenue trend Vs Pfizer, Inc. l (2007-2011) in (US $B)
Figure 8.9: APAC industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.10: ROW industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.11: North American market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.12: European market share trend Vs Pfizer, Inc. l (2007-2011) in (%)
Figure 8.13: APAC market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.14: ROW market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.15: Pfizer, Inc. trend in R&D expenses 2007-2011 in US $M
Figure 8.16: Pfizer, Inc. trend in R&D expenses Percentage of total revenue
Figure 8.17: Comparison of Pfizer, Inc. R&D expenditure vs top three & top five players average 2011
Figure 8.18: Pfizer, Inc. productivity: 2007-2011 in (US $M)
Figure 8.19: Pfizer, Inc. fixed asset value: 2007-2011 in (US $M)
Figure 8.20: Strategic execution
CHAPTER 9. Company Profile of Sanofi-Aventis
Figure 9.1: Sanofi-Aventis revenue by business structure 2011
Figure 9.2: Lucintel triad – Sanofi-Aventis
Figure 9.3: Financial benchmarking of Sanofi-Aventis against top three and top five industry players’ average
Figure 9.4: Financial benchmarking of Sanofi-Aventis against Top five best
Figure 9.5: Global industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.6: Global market share trend for Sanofi-Aventis (2007-2011) in (%)
Figure 9.7: North American industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.8: European industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.9: APAC industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.10: ROW industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.11: North American market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.12: European market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.13: APAC market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.14: ROW market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.15: Sanofi-Aventis trend in R&D expenses 2007-2011 in US $M
Figure 9.16: Sanofi-Aventis trend in R&D expenses Percentage of total revenue
Figure 9.17: Comparison of Sanofi-Aventis R&D expenditure vs top three & top five players average 2011
Figure 9.18: Sanofi-Aventis productivity: 2007-2011 in (US $M)
Figure 9.19: Sanofi-Aventis fixed asset value: 2007-2011 in (US $M)
Figure 9.20: Strategic execution
LIST OF TABLES
CHAPTER 3. Market Opportunity
Table 3.1: Industry parameters of global pharmaceutical industry
Table 3.2: Regional revenue growth rate
Table 3.3: Segment revenue growth rate
CHAPTER 4. Competitive Benchmarking (Financial and Market)
Table 4.1: Financial benchmarking of top five global pharmaceutical companies
Table 4.2: Key financial parameters for top five pharmaceutical companies
Table 4.3: Competitors based on markets served
Table 4.4: Lucintel triad - Top five major players
CHAPTER 5. Company Profile of GlaxoSmithKline Plc
Table 5.1: Market served – GlaxoSmithKline Plc
Table 5.2: Lucintel triad – GlaxoSmithKline Plc
Table 5.3: Financial Benchmarking of GlaxoSmithKline Plc against best and against Top three and top five industry players’ average
Table 5.4: Strategic execution – product positioning by segment
Table 5.5: Strategic execution – perceived customer value / quality
Table 5.6: Strategic execution – promotion / communications
Table 5.7: Strategic execution – product distribution by region
CHAPTER 6. Company Profile of Merck & Co., Inc.
Table 6.1: Market served: Merck & Co., Inc.
Table 6.2: Lucintel triad – Merck & Co., Inc.
Table 6.3: Financial Benchmarking of Merck & Co., Inc. against best and against Top three and Top five industry players’ average
Table 6.4: Strategic execution – product positioning by segment
Table 6.5: Strategic execution – perceived customer value / quality
Table 6.6: Strategic execution – promotion / communications
Table 6.7: Strategic execution – product distribution by region
CHAPTER 7. Company Profile of Novartis AG
Table 7.1: Market served – Novartis AG
Table 7.2: Lucintel triad – Novartis AG
Table 7.3: Financial benchmarking of Novartis AG against best and against Top three and Top five industry players’ average
Table 7.4: Strategic execution – product positioning by segment
Table 7.5: Strategic execution – perceived customer value / quality
Table 7.6: Strategic execution – promotion / communications
Table 7.7: Strategic execution – product distribution by region
CHAPTER 8. Company Profile of Pfizer, Inc.
Table 8.1: Market served – Pfizer, Inc.
Table 8.2: Lucintel triad – Pfizer, Inc.
Table 8.3: Financial benchmarking of Pfizer, Inc. against best and against Top three and Top five industry players’ average
Table 8.4: Strategic execution – product positioning by segment
Table 8.5: Strategic execution – perceived customer value / quality
Table 8.6: Strategic execution – promotion / communications
Table 8.7: Strategic execution – product distribution by region
CHAPTER 9. Company Profile of Sanofi-Aventis
Table 9.1: Markets Served – Sanofi-Aventis
Table 9.2: Lucintel triad – Sanofi-Aventis
Table 9.3: Financial Benchmarking of Sanofi-Aventis against best and against Top three and top five industry players’ average
Table 9.4: Strategic execution – product positioning by segment
Table 9.5: Strategic execution – perceived customer value / quality
Table 9.6: Strategic execution – promotion / communications
Table 9.7: Strategic execution – product distribution by region
CHAPTER 3. Market Opportunity
Table 3.1: Industry parameters of global pharmaceutical industry
Table 3.2: Regional revenue growth rate
Table 3.3: Segment revenue growth rate
CHAPTER 4. Competitive Benchmarking (Financial and Market)
Table 4.1: Financial benchmarking of top five global pharmaceutical companies
Table 4.2: Key financial parameters for top five pharmaceutical companies
Table 4.3: Competitors based on markets served
Table 4.4: Lucintel triad - Top five major players
CHAPTER 5. Company Profile of GlaxoSmithKline Plc
Table 5.1: Market served – GlaxoSmithKline Plc
Table 5.2: Lucintel triad – GlaxoSmithKline Plc
Table 5.3: Financial Benchmarking of GlaxoSmithKline Plc against best and against Top three and top five industry players’ average
Table 5.4: Strategic execution – product positioning by segment
Table 5.5: Strategic execution – perceived customer value / quality
Table 5.6: Strategic execution – promotion / communications
Table 5.7: Strategic execution – product distribution by region
CHAPTER 6. Company Profile of Merck & Co., Inc.
Table 6.1: Market served: Merck & Co., Inc.
Table 6.2: Lucintel triad – Merck & Co., Inc.
Table 6.3: Financial Benchmarking of Merck & Co., Inc. against best and against Top three and Top five industry players’ average
Table 6.4: Strategic execution – product positioning by segment
Table 6.5: Strategic execution – perceived customer value / quality
Table 6.6: Strategic execution – promotion / communications
Table 6.7: Strategic execution – product distribution by region
CHAPTER 7. Company Profile of Novartis AG
Table 7.1: Market served – Novartis AG
Table 7.2: Lucintel triad – Novartis AG
Table 7.3: Financial benchmarking of Novartis AG against best and against Top three and Top five industry players’ average
Table 7.4: Strategic execution – product positioning by segment
Table 7.5: Strategic execution – perceived customer value / quality
Table 7.6: Strategic execution – promotion / communications
Table 7.7: Strategic execution – product distribution by region
CHAPTER 8. Company Profile of Pfizer, Inc.
Table 8.1: Market served – Pfizer, Inc.
Table 8.2: Lucintel triad – Pfizer, Inc.
Table 8.3: Financial benchmarking of Pfizer, Inc. against best and against Top three and Top five industry players’ average
Table 8.4: Strategic execution – product positioning by segment
Table 8.5: Strategic execution – perceived customer value / quality
Table 8.6: Strategic execution – promotion / communications
Table 8.7: Strategic execution – product distribution by region
CHAPTER 9. Company Profile of Sanofi-Aventis
Table 9.1: Markets Served – Sanofi-Aventis
Table 9.2: Lucintel triad – Sanofi-Aventis
Table 9.3: Financial Benchmarking of Sanofi-Aventis against best and against Top three and top five industry players’ average
Table 9.4: Strategic execution – product positioning by segment
Table 9.5: Strategic execution – perceived customer value / quality
Table 9.6: Strategic execution – promotion / communications
Table 9.7: Strategic execution – product distribution by region
